Anixa Biosciences (ANIX) Common Equity (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Common Equity came in at $14.5 million in Q2 2026, down 2.89% YoY from $14.9 million in Q2 2025, and down 4.52% on a QoQ basis from $15.2 million in Q4 2025.
Anixa Biosciences (ANIX) Common Equity (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Common Equity data on file, last reported at $14.5 million in Q2 2026.
- Quarterly Common Equity fell 2.89% year-over-year to $14.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $14.5 million (down 2.89% YoY) and the FY2025 annual result came in at $15.2 million, down 19.73% from the prior year.
- Common Equity retreated to $14.5 million in Q2 2026, from $15.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $33.2 million in Q1 2022 to a low of $14.5 million in Q2 2026.
- A 5-year average of $22.8 million and a median of $23.4 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 154.16% — and 2025, when it slumped 33.99%.
- Tracing ANIX's Common Equity over 5 years: stood at $28.2 million in 2022, then decreased by 17.12% to $23.4 million in 2023, then retreated by 19.18% to $18.9 million in 2024, then slipped by 19.73% to $15.2 million in 2025, then slipped by 4.52% to $14.5 million in 2026.
- The last three Common Equity figures came in at $14.5 million (Q2 2026), $15.2 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Anixa Biosciences | 121.44 Mn | 121.44 Mn | - | 14.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14.48 Mn |
| Oct 31, 2025 | 15.16 Mn |
| Jul 31, 2025 | 16.60 Mn |
| Apr 30, 2025 | 14.91 Mn |
| Jan 31, 2025 | 16.71 Mn |
| Oct 31, 2024 | 18.89 Mn |
| Jul 31, 2024 | 20.69 Mn |
| Apr 30, 2024 | 22.58 Mn |
| Jan 31, 2024 | 23.60 Mn |
| Oct 31, 2023 | 23.37 Mn |
| Jul 31, 2023 | 24.59 Mn |
| Apr 30, 2023 | 25.91 Mn |
| Jan 31, 2023 | 26.91 Mn |
| Oct 31, 2022 | 28.20 Mn |
| Jul 31, 2022 | 30.91 Mn |
| Apr 30, 2022 | 31.41 Mn |
| Jan 31, 2022 | 33.24 Mn |
| Oct 31, 2021 | 34.77 Mn |
| Jul 31, 2021 | 35.85 Mn |
| Apr 30, 2021 | 37.06 Mn |